Tags

Type your tag names separated by a space and hit enter

Chemotherapy resumption in breast cancer patient after COVID-19.
Surg Case Rep. 2021 Jul 21; 7(1):170.SC

Abstract

BACKGROUND

While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2.

CASE PRESENTATION

The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy.

CONCLUSIONS

Evaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient's post-COVID-19.

Authors+Show Affiliations

Department of Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.Department of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan. ayako.nakashoji@gmail.com.Department of Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.Department of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.Department of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Setagaya-ku, Tokyo, 152-8902, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34287742

Citation

Horiguchi, Julian, et al. "Chemotherapy Resumption in Breast Cancer Patient After COVID-19." Surgical Case Reports, vol. 7, no. 1, 2021, p. 170.
Horiguchi J, Nakashoji A, Kawahara N, et al. Chemotherapy resumption in breast cancer patient after COVID-19. Surg Case Rep. 2021;7(1):170.
Horiguchi, J., Nakashoji, A., Kawahara, N., Matsui, A., & Kinoshita, T. (2021). Chemotherapy resumption in breast cancer patient after COVID-19. Surgical Case Reports, 7(1), 170. https://doi.org/10.1186/s40792-021-01253-0
Horiguchi J, et al. Chemotherapy Resumption in Breast Cancer Patient After COVID-19. Surg Case Rep. 2021 Jul 21;7(1):170. PubMed PMID: 34287742.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chemotherapy resumption in breast cancer patient after COVID-19. AU - Horiguchi,Julian, AU - Nakashoji,Ayako, AU - Kawahara,Naoki, AU - Matsui,Akira, AU - Kinoshita,Takayuki, Y1 - 2021/07/21/ PY - 2021/04/27/received PY - 2021/07/14/accepted PY - 2021/7/21/entrez PY - 2021/7/22/pubmed PY - 2021/7/22/medline KW - Breast cancer KW - COVID-19 KW - Case report KW - Chemotherapy KW - Resumption KW - Severe acute respiratory syndrome coronavirus 2 SP - 170 EP - 170 JF - Surgical case reports JO - Surg Case Rep VL - 7 IS - 1 N2 - BACKGROUND: While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2. CASE PRESENTATION: The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy. CONCLUSIONS: Evaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient's post-COVID-19. SN - 2198-7793 UR - https://www.unboundmedicine.com/medline/citation/34287742/Chemotherapy_resumption_in_breast_cancer_patient_after_COVID-19. L2 - https://dx.doi.org/10.1186/s40792-021-01253-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.